Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of PF-04965842 with background topical therapy in adolescents with moderate-to-severe atopic dermatitis
2018-003804-37Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Abrocitinib plus background medicated topical therapy with Placebo plus background medicated topical therapy (2 arms). Primary endpoint: Investigator's Global Assessment response at Week 12. Started Jan 2019; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-003804-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003804-37.